

PUBLISHED STUDIES OF WAX-MATRIX NIACIN

1. Meyers CD, Carr MC, Park S, Brunzell JD. *Varying Cost and Free Nicotinic Acid Content in OTC Niacin Preparations for Dyslipidemia*. *Annals of Internal Medicine*. 2003;139:996-1002.
2. Poon IO, Chow DS, Liang D. *Dissolution Profiles of Nonprescription Extended Release Niacin...* *Am J Health-Syst Pharm*. 2006;63:2128-2134.
3. Ivanovskaya EA, Kolomin EY, Karpov RS. *Quantitative Determination of Enduracin in Blood Serum*. *Pharmaceutical Chemistry Journal* 1998;32:48-49. (translated from Russian)
4. Figge HL, Figge J, Sourney PF, Sacks FM, et al. *Comparison of Excretion of Nicotinuric Acid After Ingestion of Two Controlled Release Nicotinic Acid Preparations in Man*. *J of Clinical Pharmacol* 1988;28:1136-1140.
5. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad SM, Grossman W. *Effect of a Modified, Well-Tolerated Niacin Regimen on Serum Total Cholesterol, High Density Lipoprotein Cholesterol and the Cholesterol to High Density Lipoprotein Ratio*. *Am J Cardiol* 1989;64:725-729
6. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang Z, Ripsin CM. *Niacin Revisited: a Randomized Controlled Trial of Wax-Matrix Sustained-Release Niacin in Hypercholesterolemia*. *Arch Intern Med* 1991;151:1424-1432.
7. Keenan JM, Wenz JB, Ripsin CM, Huang Z, McCaffrey DJ. *A Clinical Trial of Oat Bran and Niacin in the Treatment of Hyperlipidemia*. *J Fam Pract* 1992;34:313-319.
8. Keenan JM, Bae C, Fontaine PL, Wenz JB, Myers S, Huang Z, Ripsin C. *Treatment of Hypercholesterolemia: Comparison of Younger versus Older Patients Using Wax-Matrix Sustained-Release Niacin*. *J Am Geriatric Soc* 1992;40:12-18.
9. Aronov DM, Keenan JM, Akhmedzhanov NM, Perova NV, Oganov RY, Kiseleva NY. *Clinical Trial of Wax-Matrix Sustained-Release Niacin in a Russian Population With Hypercholesterolemia*. *Arch Fam Med* 1996;5:567-575.
10. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM, for the Harvard Atherosclerosis Reversibility Project (HARP) Study Group. *Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and "Normal" Cholesterol Levels*. *Annals of Internal Med*. 1996;125:529-540
11. Oganov RG, Perova NV, Kiseleva NG, Olfieriev AM, Gorskova IN, Ozerova IN, Aronov DM, Akhmedzhanov NM, Propirny GA. *Beneficial effects of wax-matrix sustained-release niacin on lipid-transport system in patients with hypercholesterolemia*. *Atherosclerosis* 1994;109:132-133.
12. Ozerova I, Kiseleva N, Olfieriev A, Kolpakova G, Aronov D, Perova N. *Effect of wax-matrix sustained-release niacin treatment on cholesterol esterification in plasma*. *Atherosclerosis* 1997;130S1:S31.
13. Kiseleva N, Olfieriev A, Oganov R. *Specific lipid response to Wax-Matrix sustained-release niacin treatment in patients with hypercholesterolemia*. *Atherosclerosis* 1999;144S1:S23
14. Keenan JM. *Sustained-Release Nicotinic Acid vs. Inositol Hexanicotinate for the Treatment of Dyslipidemia*. *Arterioscler Thromb Vasc Biol*. 2008;8:e-61-2-62 abstract from ATVB 2008.

UNPUBLISHED

15. Aronov DM, Keenan JM*, Buobnova M, Perova NV, Olfieriev F, Golubev M, National Research Centre For Preventive Medicine, Moscow. *University of Minnesota. *Effect of Sustained Release Nicotinic Acid on Post-Prandial Lipids In Patients With Coronary Artery Disease*. Presented: 7th World Congress of cardiac Rehabilitation and Secondary Prevention, Feb 20-24th, 2000, Phillipine International Convention Center, Manilla, Phillipines.